OBJECTIVE: To determine the most adequate number and size of tissue microarray (TMA) cores for pleomorphic adenoma immunohistochemical studies. STUDY DESIGN: Eighty-two pleomorphic adenoma cases were distributed in 3 TMA blocks assembled in triplicate containing 1.0-, 2.0-, and 3.0-mm cores. Immunohistochemical analysis against cytokeratin 7, Ki67, p63, and CD34 were performed and subsequently evaluated with PixelCount, nuclear, and microvessel software applications. RESULTS: The 1.0-mm TMA presented lower results than 2.0- and 3.0-mm TMAs versus conventional whole section slides. Possibly because of an increased amount of stromal tissue, 3.0-mm cores presented a higher microvessel density. Comparing the results obtained with one, two, and three 2.0-mm cores, there was no difference between triplicate or duplicate TMAs and a single-core TMA. CONCLUSIONS: Considering the possible loss of cylinders during immunohistochemical reactions, 2.0-mm TMAs in duplicate are a more reliable approach for pleomorphic adenoma immunohistochemical study.
OBJECTIVE: To determine the most adequate number and size of tissue microarray (TMA) cores for pleomorphic adenoma immunohistochemical studies. STUDY DESIGN: Eighty-two pleomorphic adenoma cases were distributed in 3 TMA blocks assembled in triplicate containing 1.0-, 2.0-, and 3.0-mm cores. Immunohistochemical analysis against cytokeratin 7, Ki67, p63, and CD34 were performed and subsequently evaluated with PixelCount, nuclear, and microvessel software applications. RESULTS: The 1.0-mm TMA presented lower results than 2.0- and 3.0-mm TMAs versus conventional whole section slides. Possibly because of an increased amount of stromal tissue, 3.0-mm cores presented a higher microvessel density. Comparing the results obtained with one, two, and three 2.0-mm cores, there was no difference between triplicate or duplicate TMAs and a single-core TMA. CONCLUSIONS: Considering the possible loss of cylinders during immunohistochemical reactions, 2.0-mm TMAs in duplicate are a more reliable approach for pleomorphic adenoma immunohistochemical study.
Authors: Samuel A Kerk; Kelsey A Finkel; Alexander T Pearson; Kristy A Warner; Zhaocheng Zhang; Felipe Nör; Vivian P Wagner; Pablo A Vargas; Max S Wicha; Elaine M Hurt; Robert E Hollingsworth; David A Tice; Jacques E Nör Journal: Clin Cancer Res Date: 2016-10-25 Impact factor: 12.531
Authors: Nicole C M Visser; Anneke A M van der Wurff; Johanna M A Pijnenborg; Leon F A G Massuger; Johan Bulten; Iris D Nagtegaal Journal: Virchows Arch Date: 2018-02-09 Impact factor: 4.064
Authors: Douglas M Guimarães; Luciana O Almeida; Manoela D Martins; Kristy A Warner; Alan R S Silva; Pablo A Vargas; Fabio D Nunes; Cristiane H Squarize; Jacques E Nör; Rogerio M Castilho Journal: Oncotarget Date: 2016-07-05
Authors: Hong Sun Kim; Yu-Chih Chen; Felipe Nör; Kristy A Warner; April Andrews; Vivian P Wagner; Zhaocheng Zhang; Zhixiong Zhang; Manoela D Martins; Alexander T Pearson; Euisik Yoon; Jacques E Nör Journal: Oncotarget Date: 2017-11-01
Authors: Claudia Cristina Biguetti; Maira Cristina Rondina Couto; Ana Claudia Rodrigues Silva; João Vitor Tadashi Cosin Shindo; Vinicius Mateus Rosa; André Luis Shinohara; Jesus Carlos Andreo; Marco Antonio Hungaro Duarte; Zhiying Wang; Marco Brotto; Mariza Akemi Matsumoto Journal: Front Endocrinol (Lausanne) Date: 2020-08-11 Impact factor: 5.555